Pharma Reaserch Prod Co Ltd (214450) - Total Liabilities

Latest as of December 2025: ₩320.01 Billion KRW ≈ $216.87 Million USD

Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has total liabilities worth ₩320.01 Billion KRW (≈ $216.87 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Pharma Reaserch Prod Co Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Pharma Reaserch Prod Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 214450 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Pharma Reaserch Prod Co Ltd Competitors by Total Liabilities

The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Viet Nam International Commercial Joint Stock Bank
VN:VIB
Vietnam ₫515.00 Trillion
KEYMED BIOSCIENCES -0001
F:64Z
Germany €1.44 Billion
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
China CN¥14.47 Billion
Also Holding AG
SW:ALSN
Switzerland CHF3.96 Billion
Sichuan Jinlu Group Co Ltd
SHE:000510
China CN¥1.54 Billion
Mach Natural Resources LP
NYSE:MNR
USA $1.81 Billion
Xiamen Solex High-Tech Industries Co Ltd
SHG:603992
China CN¥1.12 Billion
Poya International Co Ltd
TWO:5904
Taiwan NT$23.55 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Pharma Reaserch Prod Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Pharma Reaserch Prod Co Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.88 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.46 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharma Reaserch Prod Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharma Reaserch Prod Co Ltd (2015–2025)

The table below shows the annual total liabilities of Pharma Reaserch Prod Co Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩320.01 Billion
≈ $216.87 Million
+11.79%
2024-12-31 ₩286.26 Billion
≈ $193.99 Million
+291.67%
2023-12-31 ₩73.09 Billion
≈ $49.53 Million
-45.68%
2022-12-31 ₩134.55 Billion
≈ $91.18 Million
+10.10%
2021-12-31 ₩122.20 Billion
≈ $82.82 Million
+64.23%
2020-12-31 ₩74.41 Billion
≈ $50.43 Million
+22.28%
2019-12-31 ₩60.85 Billion
≈ $41.24 Million
+0.47%
2018-12-31 ₩60.56 Billion
≈ $41.04 Million
+494.87%
2017-12-31 ₩10.18 Billion
≈ $6.90 Million
+32.38%
2016-12-31 ₩7.69 Billion
≈ $5.21 Million
-38.76%
2015-12-31 ₩12.56 Billion
≈ $8.51 Million
--

About Pharma Reaserch Prod Co Ltd

KQ:214450 Korea Biotechnology
Market Cap
$2.10 Billion
₩3.10 Trillion KRW
Market Cap Rank
#6149 Global
#155 in Korea
Share Price
₩298000.00
Change (1 day)
-1.32%
52-Week Range
₩259000.00 - ₩711000.00
All Time High
₩711000.00
About

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more